Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $59 | $44 | $40 | $10 |
| % Growth | 34.1% | 10.6% | 296.8% | – |
| Cost of Goods Sold | $45 | $43 | $48 | $0 |
| Gross Profit | $14 | $1 | -$9 | $10 |
| % Margin | 23.1% | 2.9% | -21.7% | 100% |
| R&D Expenses | $314 | $241 | $156 | $135 |
| G&A Expenses | $178 | $111 | $82 | $58 |
| SG&A Expenses | $178 | $111 | $82 | $58 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1 | -$0 | -$0 |
| Operating Expenses | $493 | $351 | $237 | $193 |
| Operating Income | -$479 | -$350 | -$246 | -$183 |
| % Margin | -814.1% | -797.8% | -619.3% | -1,827.8% |
| Other Income/Exp. Net | $14 | $18 | $6 | -$4 |
| Pre-Tax Income | -$465 | -$332 | -$239 | -$186 |
| Tax Expense | -$1 | -$4 | $0 | $0 |
| Net Income | -$464 | -$328 | -$239 | -$186 |
| % Margin | -788% | -747.7% | -603.5% | -1,864.8% |
| EPS | -1.69 | -1.58 | -1.36 | -1.05 |
| % Growth | -7% | -16.2% | -29.5% | – |
| EPS Diluted | -1.69 | -1.58 | -1.36 | -1.05 |
| Weighted Avg Shares Out | 274 | 208 | 176 | 170 |
| Weighted Avg Shares Out Dil | 274 | 208 | 176 | 170 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16 | $19 | $6 | $0 |
| Interest Expense | $2 | $0 | $0 | $3 |
| Depreciation & Amortization | $36 | $24 | $12 | $8 |
| EBITDA | -$427 | -$308 | -$228 | -$175 |
| % Margin | -725.2% | -701.1% | -573.7% | -1,751.2% |